A5072978110- Glycosylation and Glycoproteins Research
- Cancer Research and Treatments
- Immunotherapy and Immune Responses
- Ubiquitin and proteasome pathways
- vaccines and immunoinformatics approaches
- Peptidase Inhibition and Analysis
- Cancer Treatment and Pharmacology
- Gastric Cancer Management and Outcomes
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- RNA modifications and cancer
- Chemotherapy-related skin toxicity
- Cancer-related cognitive impairment studies
- Monoclonal and Polyclonal Antibodies Research
- Economic and Financial Impacts of Cancer
- Glioma Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Health Systems, Economic Evaluations, Quality of Life
- Botulinum Toxin and Related Neurological Disorders
- Ethics in Clinical Research
- Plant-based Medicinal Research
- Cancer survivorship and care
- Helicobacter pylori-related gastroenterology studies
Mayo Clinic in Arizona
2018-2023
Mayo Clinic
2018-2023
WinnMed
2022
Alliance Data (United States)
2019-2021
Mayo Clinic in Florida
2020
To assess whether MUC1 peptide vaccine produces an immune response and prevents subsequent colon adenoma formation.
<h3>Importance</h3> Nearly 96% of patients with high-grade glioma (HGG) report moderate-to-severe fatigue. Armodafinil is a psychostimulant that might help cancer-related fatigue in HGG. <h3>Objective</h3> To determine whether armodafinil reduces HGG and <h3>Design, Setting, Participants</h3> In this randomized multicenter, phase 3, double-blinded, placebo-controlled clinical trial, adults who were clinically stable at least 4 weeks after completing radiation therapy to receive daily (150 mg...
Importance Patients with familial adenomatous polyposis (FAP) are at markedly increased risk for duodenal adenomas and cancer. Combination sulindac erlotinib was previously shown to reduce polyp burden but associated a relatively high adverse event (AE) rate. Objective: To evaluate if once weekly dosing schedule intervention improves the AE profile, while still providing efficacy respect reduced burden, in participants FAP. Design, setting participants: Single-arm trial, enrolling 46 FAP,...
Guanylyl cyclase C (GUCY2C) is a tumor-suppressing receptor silenced by loss of expression the luminocrine hormones guanylin and uroguanylin early in colorectal carcinogenesis. This observation suggests oral replacement with GUCY2C agonist may be an effective targeted chemoprevention agent. Previous studies revealed that linaclotide, formulated for gastric release, did not persist to activate guanylyl signaling distal rectum. Dolcanatide investigational analog, substituted select D amino...
Less than 3% of older patients with cancer are enrolled in clinical trials. To reverse this underrepresentation, we compared older-patient-specific trials, defined as those designed for cancer, age-unspecified
<p>supplementary methods: trial administration</p>
<p>MUC1 expression and immune infiltrate in baseline recurrent adenoma pairs</p>
<p>supplementary methods: Detailed laboratory methods</p>
<p>supplementary methods: Detailed laboratory methods</p>
<p>MUC1 expression and immune infiltrate in baseline recurrent adenoma pairs</p>